Abolism of an atypical antipsychotic agent, 3-[4-[4-(6- fluorobenzo[b]thien-3-yl)-1-piperazlnyl]butyl]-2,5,5-trimethyl-4- thiazolidinone (HP236)

Drug Metabolism and Disposition

Volumn 24, Issue 10, 1996, Pages 1139-1150

  Mutlib, A E ^a,b   Jurcak, J ^a   Hrib, N ^a  

^a Neuroscience Product Group Unit   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HP 236; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG; THIAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG METABOLISM; DRUG STRUCTURE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; ANIMAL; BIOTRANSFORMATION; LIVER MICROSOME; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; WISTAR RAT;

ANIMALIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; RATS; RATS, WISTAR; THIAZOLES; THIAZOLIDINES;

EID: 0029658516     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. K. L. Rogers, H. B. Hartman, J. E. Roehr, A. M. Szczepanik, C. A. Wilmot, L. R. Broughman, D. E. Bregna, M. R. Szewczak, N. J. Hrib, J. G. Jurcak, and P. G. Conway: Neurochemical and electrophysiological properties of the potential atypical antipsychotic drug, P-9236. Poster presented at the Third IBRO World Congress of Neuroscience, Montreal, Canada, August 1991, Abstract P31.43.
2. N. J. Hrib, J. G. Jurcak, D. E. Bregna, R. W. Dunn, H. M. Geyer, H. B. Hartman, I. E. Roehr, K. L. Rogers, D. K. Rush, A. M. Szczepanik, M. R. Szewczak, C. A. Wilmot, and P. G. Conway: 3-[4-[1-(6-Fluorobenzo-[b]thiophen-3-yl)-4-piperazinyl]butyl]-2,5,5-trimethyl-4- thiazolidinone: a new atypical antipsychotic agent for the treatment of schizophrenia. J. Med. Chem. 35, 2712-2715 (1992).
3. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall: Protein measurement with the FoUn reagent. J. Biol. Chem. 193, 265-275 (1951).
4. A. E. Mutlib and J. T. Strupczewski: Picogram determination of iloperidone in human plasma by solid phase extraction and by high performance liquid chromatography/selected ion monitoring electrospray mass spectrometry. J. Chromatogr. B. Biomed. Appl. 669, 237-246 (1995).
5. K. Mizuno, T. Sohda, K. Meguro, Y. Kawamatsu, and Y. Yamamoto: Studies on antidiabetic agents. V. Synthesis of the metabolites of 5-(3-ethoxy-4-pentyloxyphenyl)-2,4-thiazolidinone (CT-112) and related compounds. Takeda Kenkyushoho 42, 227-237 (1983).
6. F. Gachon, C. Nicolas, J. C. Maurizis, M. Verny, J. L. Chabard, M. Faurie, and G. Gaillard: Disposition and metabolism of letosteine in rats. Drug Metab. Dispos. 16, 853-857 (1988).
7. G. Gosa, O. Caputo, M. Ceruti, and G. Biglino: Metabolism of 7-(1,3-thiazolidin-2-ylmethyl)theophylline by rat liver microsomes. Evidence for a monooxygenase-dependent step in 1,3-thiazolidine ring cleavage. Drug Metab. Dispos. 20, 742-746 (1992).
8. T. H. Fife, R. Natarajan, C. C. Shen, and R. Bembi: Mechanism of thiazolidine hydrolysis. Ring opening and hydrolysis of 1,3-thiazolidine derivatives of p-(dimethylamino)cinnamaldehyde. J. Am. Chem. Soc. 113, 3071-3079 (1991).
9. J. J. Pesek and J. H. Frost: Decomposition of thiazolidines in acidic and basic solution. Spectroscopic evidence for Schiff base intermediates. Tetrahedron 31, 907-913 (1975).
10. R. B. Morin, B. G. Jackson, R. A. Mueller, E. R. Lavagnino, W. B. Scanlon, and S. L. Andrews: Chemistry of cephalosporin antibiotics. XV. Transformations of penicillin sulfoxide. A synthesis of cephalosporin compounds. J. Am. Chem. Soc. 91, 1401-1407 (1969).